Analysis of mucosal concentrations of biologics in Crohn's disease

Analysis of mucosal concentrations of biologics in Crohn's disease - Analysis of mucosal concentrations of biologics in Crohn's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045241

Enrollment

200

Registered

2021-09-01

Start date

2021-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Ileal or ileocolonic Crohn's disease 2. Recieving biologics (infliximab, adalimumab, ustekinumab, vedolizumab). 3. Plan to undergo balloon-assisted enteroscopy for intestinal evaluation.

Exclusion criteria

Exclusion criteria: 1. Colonic Crohn's disease 2. Patients with artificial anus 3. Patients who cannot insert a balloon assisted enteroscopy 4. Patients with serious intestinal infections 5. Patients with a history of malignant tumors 6. Patients with tuberculosis or hepatitis B activity 7. Pregnant patients 8. Patients with bleeding tendency

Design outcomes

Primary

Measure	Time frame
Relationship between mucosal healing and mucosal concentrations	—

Countries

Japan

Contacts

Public ContactKento Takenaka

Tokyo Medical and Dental University Gastroenterology and Hepatology

ktakenaka.gast@tmd.ac.jp03-5803-5877

Outcome results